Cargando…
Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting muscarinic antagonist [LAMA] plus a long-acting β(2)-agonist [LABA]) are available for the treatment of COPD. Studies of these FDCs have demonstrated substantial improvements in lung function (forced expiratory volu...
Autores principales: | Price, David, Østrem, Anders, Thomas, Mike, Welte, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221557/ https://www.ncbi.nlm.nih.gov/pubmed/28115839 http://dx.doi.org/10.2147/COPD.S116719 |
Ejemplares similares
-
When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017) -
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019) -
Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019) -
Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021) -
PREFUL MRI Depicts Dual Bronchodilator Changes in COPD: A
Retrospective Analysis of a Randomized Controlled Trial
por: Voskrebenzev, Andreas, et al.
Publicado: (2022)